{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:56:30Z","timestamp":1787007390276,"version":"build-2736575974"},"reference-count":124,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2022,6,3]]},"DOI":"10.1080\/14760584.2022.2064850","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T03:50:05Z","timestamp":1650945005000},"page":"753-769","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-4043","authenticated-orcid":false,"given":"Jamie","family":"Findlow","sequence":"first","affiliation":[{"name":"Vaccine Medical Development, Scientific and Clinical Affairs, Pfizer Ltd, Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-6568","authenticated-orcid":false,"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Woodruff Health Sciences Center, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Liberator","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-1791","authenticated-orcid":false,"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Vaccine Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[{"name":"Vaccine Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.079"},{"key":"cit0002","doi-asserted-by":"crossref","unstructured":"Purmohamad A, Abasi E, Azimi T, et al. Global estimate of\n                      Neisseria meningitidis\n                      serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019; 134:103571.","DOI":"10.1016\/j.micpath.2019.103571"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0906357"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441807"},{"issue":"2","key":"cit0005","first-page":"1","volume":"62","author":"Cohn AC","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"cit0006","volume-title":"GlaxoSmithKline Vaccines srl","author":"Bexsero (MenB-4C)","year":"2018"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30400-6"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1940144"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.070"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.091"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.08.031"},{"issue":"2","key":"cit0013","first-page":"195","volume":"14","author":"Sierra GV","year":"1991","journal-title":"NIPH Ann"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91961-S"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24129"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1080\/1040841X.2017.1329276"},{"issue":"7","key":"cit0017","first-page":"734","volume":"21","author":"Holst J","journal-title":"Vaccine"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264750"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00230-06"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00423-5"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.12.031"},{"key":"cit0022","volume-title":"16th International Pathogenic Neisseria Conference","author":"Rots NY","year":"2008"},{"key":"cit0023","unstructured":"US Food and Drug Administration.\n                      Summary Basis for Regulatory Action\n                      . 2014 October 29. [cited 2018 Oct 11]; Available from: https:\/\/wayback.archive-it.org\/7993\/20190425012126\/https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM424125.pdf."},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181f59f6d"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1086\/656741"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix154"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030469"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901229"},{"key":"cit0029","unstructured":"Bexsero\u00ae. Summary of Product Characteristics.\n                      GlaxoSmithKline\n                      , in\n                      4CMenB\n                      . 2019."},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"cit0031","unstructured":"European Medicines Agency.\n                      Bexsero EPAR summary for the public\n                      . 2012. [cited 2017 Mar 27]; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002333\/WC500137857.pdf."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9979-x"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34293"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1086\/600141"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.083"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70006-9"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00036-18"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01071-08"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.501"},{"key":"cit0041","unstructured":"Neisseria factor H binding protein sequence typing\n                      . 2020. [cited 2020 Oct 12]; Available from: https:\/\/pubmlst.org\/neisseria\/fHbp\/."},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.14826.1"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.064"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002957"},{"issue":"1","key":"cit0046","doi-asserted-by":"crossref","first-page":"e00430","DOI":"10.1128\/CVI.00430-16","volume":"24","author":"Giuntini S","year":"2017","journal-title":"Clin Vaccin Immunol"},{"key":"cit0047","unstructured":"NadA sequence typing\n                      . 2020. [cited 2020 Oct 12]; Available from: https:\/\/pubmlst.org\/neisseria\/NadA\/."},{"key":"cit0048","unstructured":"Neisserial heparin binding antigen (NHBA) protein sequence typing\n                      . 2020. [cited 2020 Oct 12]; Available from: https:\/\/pubmlst.org\/neisseria\/NHBA\/."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00825-13"},{"issue":"5","key":"cit0050","doi-asserted-by":"crossref","first-page":"e01914","DOI":"10.1128\/mBio.01914-18","volume":"9","author":"Liguori A","year":"2018","journal-title":"mBio"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.020"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013758107"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01085-12"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1086\/315833"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.486-491.2006"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00038-06"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00261-17"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.6.15482"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00039-07"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22057-7"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.081"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1244"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.01.066"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00121-17"},{"issue":"24","key":"cit0065","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","volume":"347","author":"Ostergaard L","year":"2017","journal-title":"N Engl J Med"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61713-3"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1816"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0155-7"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00751"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.014"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.015"},{"key":"cit0072","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fmicb.2019.02847","volume":"10","author":"da Silva RAG","year":"2019","journal-title":"Front Microbiol"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1514866"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.07.034"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.061"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.08.015"},{"issue":"1","key":"cit0077","first-page":"e02161","volume":"59","author":"Rodrigues CMC","year":"2020","journal-title":"J Clin Microbiol"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.12.005"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1627159"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.059"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.027"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.071"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001896"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.7.15997"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1483726"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0154-0"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70087-7"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.01.030"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.051"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241793"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243375"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.073"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001399"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-4015"},{"key":"cit0095","volume-title":"Meningococcal B vaccine (4CMenB) immunogenicity pre- and postvaccination among university students in the US. Presented at: 36th Annual European Society for Paediatric Infectious Diseases (ESPID) Meeting","author":"Basta N","year":"2018"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1537756"},{"key":"cit0097","unstructured":"Pfizer Inc. Data on file: Final Clinical Study Report: a phase 4, single-arm, open-label study describing the safety and immunogenicity of Bexsero in healthy subjects aged between 12 and <19 years.\n                      B1971048\n                      . 2016."},{"key":"cit0098","unstructured":"EU Clinical Trials Register.\n                      A Phase 4, Single-Arm, Open-Label Study Describing The Safety And Immunogenicity of Bexsero in Healthy Subjects Aged 12 Years to Less Than (<) 19 Years\n                      . [cited 2021 Mar 26]: Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-003822-42\/results."},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.050"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00370-x"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.3201\/eid2202.150369"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002957"},{"key":"cit0103","volume-title":"Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease: briefing document for the Vaccines and Related Biologic Product Advisory Committee Meeting, April 7","author":"Vaccines and Related Biologic Products Advisory Committee","year":"2011"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.3201\/eid2503.181574"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.051"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1086\/527401"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.025"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107240"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.038"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.161288"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.009"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001056"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.073"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0254-1"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900236"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa610"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix091"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix446"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037358"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"cit0121","volume-title":"Full Prescribing Information, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc","author":"TRUMENBA\u00ae (Meningococcal Group B Vaccine)","year":"2018"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1457595"},{"issue":"1","key":"cit0123","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/ofid\/ofaa439.051","volume":"7","author":"Peterson J","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"cit0124","first-page":"e00462","volume":"88","author":"Tzeng Y-L","year":"2020","journal-title":"Infect Immun"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2022.2064850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T14:10:06Z","timestamp":1654870206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2022.2064850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1080\/14760584.2022.2064850"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2022.2064850","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}